Catalent Inc. Investors Advance Narrowed Quality, Revenue Claims

Catalent Inc. shareholders can continue with a proposed class action alleging the vaccine manufacturer misled them about quality control and sustained revenue, but not all their allegations about those issues made it through, a federal court said.

The investors can’t proceed with claims over Catalent’s statements about demand for its gene therapy and other non-vaccine products, Judge Zahid N. Quraishi said June 28 for the US District Court for the District of New Jersey.

The suit is among a number targeting vaccine and drug company statements and business tactics as the Covid-19 pandemic developed and eventually eased. Still other suits ...